GRAL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

3 Analyst Rating

Wall Street analysts forecast GRAL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRAL is 60.86 USD with a low forecast of 38.00 USD and a high forecast of 83.71 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

38.00

Averages

60.86

High

83.71

Current: 0.000

Low

38.00

Averages

60.86

High

83.71

Canaccord

Kyle Mikson

Buy

maintain

$85 -> $105

2025-11-17

Reason

Canaccord

Kyle Mikson

Price Target

$85 -> $105

2025-11-17

maintain

Buy

Reason

Canaccord analyst Kyle Mikson raised the firm's price target on Grail to $105 from $85 and keeps a Buy rating on the shares. The firm target increase is driven by significant progress/plans to expand adoption levels (and reimbursement) for the Galleri multi-cancer early detection (MCED) test.

Morgan Stanley

Equal Weight

maintain

$38 -> $85

2025-11-16

Reason

Morgan Stanley

Price Target

$38 -> $85

2025-11-16

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Grail to $85 from $38 and keeps an Equal Weight rating on the shares. The firm updated the company's estimates post the Q3 report. It cites Grail's longer-term opportunity with Galleri for the target increase. The multi-cancer early detection test has significant long-term potential, but there are also inherent risks associated with novel technologies, the analyst tells investors in a research note.

Guggenheim

Subbu Nambi

Neutral -> Buy

upgrade

$100

2025-11-12

Reason

Guggenheim

Subbu Nambi

Price Target

$100

2025-11-12

upgrade

Neutral -> Buy

Reason

Guggenheim analyst Subbu Nambi upgraded Grail to Buy from Neutral with a $100 price target.

Guggenheim

Subbu Nambi

Neutral -> Buy

upgrade

$100

2025-11-12

Reason

Guggenheim

Subbu Nambi

Price Target

$100

2025-11-12

upgrade

Neutral -> Buy

Reason

As previously reported, Guggenheim analyst Subbu Nambi upgraded Grail to Buy from Neutral with a $100 price target. While the firm acknowledges that Galleri is "not a perfect test" and "may not be the holy grail of cancer detection," the firm says it is still the leading commercially available MCED test and sees it having a significant prospective data moat compared to competitors. Though there are still meaningful unknowns around Medicare reimbursement for MCEDs and regulatory approvals, the firm says it "cannot ignore the opportunity" and Galleri's leading MCED market position.

Canaccord

Kyle Mikson

Buy

upgrade

$75 -> $85

2025-10-22

Reason

Canaccord

Kyle Mikson

Price Target

$75 -> $85

2025-10-22

upgrade

Buy

Reason

Canaccord analyst Kyle Mikson raised the firm's price target on Grail to $85 from $75 and keeps a Buy rating on the shares. The firm said they remain bullish following relatively positive study results and over $400 million (pending) added to the company's balance sheet, recognizing multiple questions remain regarding the perspective of regulators and clinicians. They also noted that after the market close on Friday, October 17, the company announced the performance and safety results from its registrational PATHFINDER 2 study and saidalthough the data improved from PATHFINDER 1, it is unclear if it will be adequate for FDA approval.

Morgan Stanley

Equal Weight

initiated

$20 -> $38

2025-06-26

Reason

Morgan Stanley

Price Target

$20 -> $38

2025-06-26

initiated

Equal Weight

Reason

Morgan Stanley assumed coverage of Grail with an Equal Weight rating and a price target of $38, up from $20. While the firm sees significant long-term potential for Grail's Galleri MCED test, there are also inherent risks associated with novel technologies from a regulatory and reimbursement standpoint, the analyst tells investors. The firm is also updating estimates for Q1 results, noting that its Q2 and 2025 revenue estimates move to $36M and $151M, from prior forecasts of $37M and $149M, respectively.

Valuation Metrics

The current forward P/E ratio for Grail Inc (GRAL.O) is -7.36, compared to its 5-year average forward P/E of -2.44. For a more detailed relative valuation and DCF analysis to assess Grail Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.44

Current PE

-7.36

Overvalued PE

-0.02

Undervalued PE

-4.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.18

Current EV/EBITDA

-9.08

Overvalued EV/EBITDA

0.89

Undervalued EV/EBITDA

-5.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

7.69

Current PS

21.23

Overvalued PS

14.33

Undervalued PS

1.04

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

GRAL News & Events

Events Timeline

No data

News

1.0

2025-12-15PRnewswire

GRAIL to Present Early Cancer Detection Technology at J.P. Morgan Healthcare Conference

8.5

2025-11-20WSJ

Abbott Set to Purchase Exact Sciences for $21 Billion

1.0

2025-11-18PRnewswire

GRAIL to Present at Piper Sandler 37th Annual Healthcare Conference

People Also Watch

Frequently Asked Questions

What is Grail Inc (GRAL) stock price today?

The current price of GRAL is 100.1 USD — it has increased 2.1 % in the last trading day.

What is Grail Inc (GRAL)'s business?

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

What is the price predicton of GRAL Stock?

What is Grail Inc (GRAL)'s revenue for the last quarter?

Grail Inc revenue for the last quarter amounts to 36.19M USD, increased 26.32 % YoY.

What is Grail Inc (GRAL)'s earnings per share (EPS) for the last quarter?

Grail Inc. EPS for the last quarter amounts to -2.46 USD, decreased -37.56 % YoY.

What changes have occurred in the market's expectations for Grail Inc (GRAL)'s fundamentals?

The market is revising Upward the revenue expectations for GRAIL, Inc. (GRAL) for FY2025, with the revenue forecasts being adjusted by 1.23% over the past three months. During the same period, the stock price has changed by 51.37%.

How many employees does Grail Inc (GRAL). have?

Grail Inc (GRAL) has 1000 emplpoyees as of January 10 2026.

What is Grail Inc (GRAL) market cap?

Today GRAL has the market capitalization of 3.90B USD.